8i Acquisition 2 Corp.: directors' dealings · United States · SEC (Form 4)

About 8i Acquisition 2 Corp.

8i Acquisition 2 Corp. was originally formed on January 21, 2021 as a blank check company, or SPAC, in the British Virgin Islands for the purpose of completing a merger, share exchange, asset acquisition, or similar business combination with one or more target businesses. For equity investors, the key point is that the company has already completed its business combination and changed its name to EUDA Health Holdings Limited. In other words, it no longer functions as a pure shell, although its SEC filings and insider transaction disclosures remain highly relevant for tracking the investment case. The security has been associated with the NASDAQ market in the United States, which places it within the universe of US-listed securities followed closely through SEC reporting, including Form 4 insider activity. Operationally, the post-combination group is positioned as a healthcare and related-services platform with three main operating segments disclosed in SEC filings: specialty healthcare and general practice clinic services; property management services for shopping malls, office buildings, and residential apartments; and a holistic wellness business offering bioenergy capsules and supplement products aimed at general chronic conditions. This is an unusual mix, reflecting the post-SPAC build-out of a multi-activity group rather than a conventional single-line healthcare company. The company’s core operating presence is in Singapore, while its legal structure remains tied to the British Virgin Islands and its equity story remains connected to US public-market disclosure requirements. From a history and founding perspective, 8i was launched as a vehicle to find and merge with an operating business. The transformative event was the business combination with EUDA Health Limited, which closed on November 17, 2022, after which the company adopted the EUDA Health Holdings Limited name. That transaction marked the shift from blank-check status to an operating company with execution risk, integration challenges, and a need to build recurring revenues and credibility with public-market investors. In competitive terms, the company remains relatively small and niche-focused compared with larger US-listed healthcare groups. Its positioning is less about scale leadership and more about combining specialty care, managed property-related services, and wellness offerings under one corporate umbrella. That makes the equity story more speculative and dependent on management execution, capital allocation discipline, and the ability to convert acquired assets into sustainable cash generation. Recent developments visible in SEC materials suggest the company remains active in regulatory reporting, with ongoing attention to securities transactions and insider activity through Form 4 filings. For investors in the United States, the core question is whether the post-SPAC transition can translate into durable operating performance and greater visibility on the NASDAQ-listed market.